International progress in cancer gene therapy

Cancer Gene Therapy

Volumn 15, Issue 12, 2008, Pages 765-775

  Guinn, B A ^a   Mulherkar, R ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Research and Education in Cancer   (India)

Author keywords

Cancer research; Immunotherapy; International Society for the Cell and Gene Therapy of Cancer

Indexed keywords

CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; INDIA; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INDIA; MICE; NEOPLASMS; ONCOLYTIC VIRUSES; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY;

EID: 56049106797     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.66     Document Type: Review

References (83)

1. de Bruijn DR, dos Santos NR, Kater-Baats E, Thijssen J, van den BerkL, Stap J et al. The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer 2002; 34: 285-298.
2. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S et al. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 335: 1293-1304.
3. Denniss FA, Breslin A, Ingram W, HardwickNR, Mufti GJ, Guinn BA. The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. Br J Haematol 2007; 138: 668-669.
4. Guinn BA, Bullinger L, Thomas NS, Mills KI, Greiner J. SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol 2008; 140: 250-251.
5. Zachariae W, Nasmyth K. Whose end is destruction: cell division and the anaphase-promoting complex. Genes Develop 1999; 13: 2039-2058.
6. Boyapati A, Yan M, Peterson LF, Biggs JR, Le Beau MM, Zhang DE. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood 2007; 109: 3963-3971.
7. Wajapeyee N, Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2α(AP-2α) and the role of p53 and p21WAF1/CIP1 in AP-2α-mediated growth inhibition. J Biol Chem 2003; 278: 52093-52101.
8. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. Apoptosis induction by activator protein 2α involves transcriptional repression of Bcl-2. J Biol Chem 2006; 281: 16207-16219.
9. Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN et al. Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res 2008; 14: 41-47.
10. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 2002; 62: 2715-2720.
11. Ito I, Began G, Mohiuddin I, Saeki T, Saito Y, Branch CD et al. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther 2003; 7: 409-418.
12. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004; 11: 733-739.
13. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA, Ramesh R. Nanoparticle-based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 2004; 3: 647-657.
14. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy - what have we learned? J Neuro-Oncol 2003; 65: 227-236.
15. Thomas SM, Naresh KN, Wagle AS, Mulherkar R. Preclinical studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of treatment efficacy. Anticancer Res 1998; 18: 4393-4398.
16. Wagle AS, Joshi GV, Naresh KN, Mulherkar R. Preclinical studies for gene therapy of head and neck cancers using the HSV-tk/GCV strategy. Indian J Biotechnol 2005; 4: 82-87.
17. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233-2240.
18. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687-1692.
19. Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D et al. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 2005; 116: 314-321.
20. Ma H, Liu Y, Liu S, Xu R, Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005; 42: 1355-1363.
21. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005; 280: 41940-41952.
22. Shi J, Liu Y, Zheng Y, Guo Y, Zhang J, Cheung PT et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res 2006; 66: 11946-11953.
23. Lin C, Wei W, Zhang J, Liu S, Liu Y, Zheng D. Formyl peptide receptor-like one mediated endogenous TRAIL gene expression with tumoricidal activity. Mol Cancer Ther 2007; 6: 2618-2625.
24. Collins CG, Tangney M, Larkin JO, Casey G, Whelan MC, Cashman J et al. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors. Cancer Gene Ther 2006; 13: 1061-1071.
25. Wang ZG, Zhao W, Ramachandra M, Seth P. An oncolytic adenovirus expressing soluble transforming growth factor-βtype II receptor for targeting breast cancer: in vitro evaluation. Mol Cancer Ther 2006; 5: 367-373.
26. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995; 1: 889-897.
27. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5-13.
28. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Human Gene Ther 2005; 16: 1016-1027.
29. Wadler S, Yu B, Tan JY, Kaleya R, Rozenblit A, Makower D et al. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res 2003; 9: 33-43.
30. Warren RS, Kirn DH. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg Oncol Clin North Am 2002; 11: 571-588.
31. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
32. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359-6366.
33. Miyauchi M, Shimada H, Kadomatsu K, Muramatsu T, Matsubara S, Ikematsu S et al. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 1999; 90: 469-475.
34. Lo HL, Chang T, Yam P, Marcovecchio PM, Li S, Zaia JA et al. Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters. Gene Ther 2007; 14: 1503-1512.
35. Miletic H, Fischer YH, Giroglou T, Rueger MA, Winkeler A, Li H et al. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 2007; 13: 6761-6768.
36. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006; 14: 118-128.
37. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004; 11: 1256-1263.
38. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target 2007; 15: 546-551.
39. Stevenson M, Hale AB, Hale SJ, Green NK, Black G, Fisher KD et al. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via α6-integrins. Cancer Gene Ther 2007; 14: 335-345.
40. Teichler Zallen D. US gene therapy in crisis. Trends Genet 2000; 16: 272-275.
41. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med 2003; 348: 255-256.
42. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
43. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107-114.
44. Thrasher AJ. Gene therapy for primary immunodeficiencies. Immunol Allergy Clin North Am 2008; 28: 457-471.
45. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005; 105: 4255-4257.
46. Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, Glimm H et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007; 117: 2241-2249.
47. Chan L, Hardwick NR, Guinn BA, Darling D, Gaken J, Galea-Lauri J et al. An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol, Immunother 2006; 55: 1017-1024.
48. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970-977.
49. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413-1422.
50. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004; 108: 704-711.
51. Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002; 16: 2238-2242.
52. Guinn BA, Gilkes AF, Woodward E, Westwood NB, Mufti GJ, Linch D et al. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 333: 703-713.
53. Hirano N, Takahashi T, Takahashi T, Ohtake S, Hirashima K, Emi N et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168-1176.
54. Maeda A, Yamamoto K, Yamashita K, Asagoe K, Nohgawa M, Kita K et al. The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. Br J Haematol 1998; 102: 1257-1262.
55. Tsukada N, Aoki S, Maruyama S, Kishi K, Takahashi M, Aizawa Y. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J Exp Clin Cancer Res 1997; 16: 171-176.
56. Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791-1796.
57. Hirst WJ, Buggins A, Darling D, Gaken J, Farzaneh F, Mufti GJ. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther 1997; 4: 691-699.
58. Chan L, HardwickN, Darling D, Galea-Lauri J, Gaken J, Devereux S et al. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 2005; 11: 120-131.
59. Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev 2002; 2: 263-272.
60. Jost PJ, Harbottle RP, Knight A, Miller AD, Coutelle C, Schneider H. A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett 2001; 489: 263-269.
61. Kostarelos K, Miller AD. What role can chemistry play in cationic liposome-based gene therapy research today? Adv Genet 2005; 53PA: 69-118.
62. Kostarelos K, Miller AD. Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem Soc Rev 2005; 34: 970-994.
63. Miller AD. The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy. Curr Med Chem 2003; 10: 1195-1211.
64. Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 2006; 5: 1975-1985.
65. Tang Y, Zhang L, Yuan J, Akbulut H, Maynard J, Linton PJ et al. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. Blood 2004; 104: 2704-2713.
66. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100: 15101-15106.
67. Gershon RK, Cohen P, Hencin R, Liebhaber SA. Suppressor T cells. J Immunol 1972; 108: 586-590.
68. Gershon RK, Mokyr MB, Mitchell MS. Activation of suppressor T cells by tumour cells and specific antibody. Nature 1974; 250: 594-596.
69. Hall BM. Mechanisms maintaining enhancement of allografts. I. Demonstration of a specific suppressor cell. J Exp Med 1985; 161: 123-133.
70. Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med 1985; 162: 1683-1694.
71. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161: 72-87.
72. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
73. Raimondi G, Turner MS, Thomson AW, Morel PA. Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 2007; 27: 61-95.
74. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180.
75. Terrada C, Fisson S, De KozakY, Kaddouri M, Lehoang P, Klatzmann D et al. Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J Immunol 2006; 176: 7171-7179.
76. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
77. Marodon G, Fisson S, Levacher B, Fabre M, Salomon BL, Klatzmann D. Induction of antigen-specific tolerance by intrathymic injection of lentiviral vectors. Blood 2006; 108: 2972-2978.
78. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-790.
79. Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset FL et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006; 24: 2643-2655.
80. Vyas GN, Rao KR, Ibrahim AB. Australia antigen (hepatitis B antigen): a conformational antigen dependent on disulfide bonds. Science 1972; 178: 1300-1301.
81. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262: 1448-1451.
82. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172: 1777-1785.
83. Dreux M, Cosset FL. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepatol 2007; 14: 68-76.